Ray of dawn: Anti-PD-1 immunotherapy enhances the chimeric antigen receptor T-cell therapy in Lymphoma patients

BACKGROUND: Chimeric antigen receptor T (CAR-T) cell therapy, a new adoptive cell therapy, has been widely used to treat lymphoma patients. Immune checkpoint blockade may improve the cytotoxicity of CAR-T cells by reducing the failure of CAR-T cells and improving antitumor activity. It has shown pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Yuxin, Mu, Wenjing, Wang, Chen, Zhuo, Zipeng, Xin, Yu, Li, Hongxu, Wang, Changsong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10591343/
https://www.ncbi.nlm.nih.gov/pubmed/37872514
http://dx.doi.org/10.1186/s12885-023-11536-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10591343/
https://www.ncbi.nlm.nih.gov/pubmed/37872514
http://dx.doi.org/10.1186/s12885-023-11536-4

Ejemplares similares